open access

Vol 14, No 5 (2018)
Guidelines / Expert consensus
Get Citation

Long-term intravenous access in cancer patients

Elwira Góraj, Małgorzata Lipiec
DOI: 10.5603/10.5603/OCP.2018.0033
·
Oncol Clin Pract 2018;14(5):257-271.

open access

Vol 14, No 5 (2018)
GUIDELINES FOR DIAGNOSTIC AND THERAPEUTIC MANAGEMENT IN MALIGNANT NEOPLASMS 2018

Abstract

Not available

Abstract

Not available
Get Citation

Keywords

totally implantable venous access devices (TIVADs); intravenous chemiotherapy; catheter-related bloodstream infections; catheter-related thrombosis

About this article
Title

Long-term intravenous access in cancer patients

Journal

Oncology in Clinical Practice

Issue

Vol 14, No 5 (2018)

Article type

Guidelines / Expert consensus

Pages

257-271

DOI

10.5603/10.5603/OCP.2018.0033

Bibliographic record

Oncol Clin Pract 2018;14(5):257-271.

Keywords

totally implantable venous access devices (TIVADs)
intravenous chemiotherapy
catheter-related bloodstream infections
catheter-related thrombosis

Authors

Elwira Góraj
Małgorzata Lipiec

References (38)
  1. Sousa B, Furlanetto J, Hutka M, et al. ESMO Guidelines Committee. Central venous access in oncology: ESMO Clinical Practice Guidelines. Ann Oncol. 2015; 26 Suppl 5: v152–v168.
  2. Młynarski R. VI Sympozjum „Port dożylny – implantacja, pielęgnacja, powikłania” liczba implantacji. Próba usystematyzowania terminologii dotyczącej portów dożylnych. Wiad Lek. 2015; 68(1): 111–114.
  3. Di CI, Biffi R. Totally Implanted Venous Access Devices. Springer 2012: 87.
  4. Bishop L, Dougherty L, Bodenham A, et al. Guidelines on the insertion and management of central venous access devices in adults. Int J Lab Hematol. 2007; 29(4): 261–278.
  5. Schiffer CA, Mangu PB, Wade JC, et al. Central venous catheter care for the patient with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2013; 31(10): 1357–1370.
  6. Młynarski R, Misiak M, Leś J, et al. Zasady obsługi portów dożylnych. Zalecenia polskiego klubu dostępu naczyniowego. Med. Prakt. 2016; 7-8: 24–27.
  7. Korte W, Cattaneo M, Chassot PG, et al. Peri-operative management of antiplatelet therapy in patients with coronary artery disease: joint position paper by members of the working group on Perioperative Haemostasis of the Society on Thrombosis and Haemostasis Research (GTH), the working group on Perioperative Coagulation of the Austrian Society for Anesthesiology, Resuscitation and Intensive Care (ÖGARI) and the Working Group Thrombosis of the European Society for Cardiology (ESC). Thromb Haemost. 2011; 105(5): 743–749.
  8. López-Briz E, Ruiz Garcia V, Cabello JB, Bort-Marti S, CarbonellSanchis R, Burls A . CochraneDatabase of Systematic Reviews 2014; 10: CD008462. 2014.
  9. Watters VA, Grant JP. Use of electrocardiogram to position right atrial catheters during surgery. Ann Surg. 1997; 225(2): 165–171.
  10. Hayashi H, Amano M. Does ultrasound imaging before puncture facilitate internal jugular vein cannulation? Prospective randomized comparison with landmark-guided puncture in ventilated patients. J Cardiothorac Vasc Anesth. 2002; 16(5): 572–575.
  11. Nakazawa N. Challenges in the Accurate Identification of the Ideal Catheter Tip Location. Journal of the Association for Vascular Access. 2010; 15(4): 196–201.
  12. Caers Jo, Fontaine C, Vinh-Hung V, et al. Catheter tip position as a risk factor for thrombosis associated with the use of subcutaneous infusion ports. Support Care Cancer. 2005; 13(5): 325–331.
  13. Vescia S, Baumgärtner AK, Jacobs VR, et al. Management of venous port systems in oncology: a review of current evidence. Ann Oncol. 2008; 19(1): 9–15.
  14. Patel GS, Jain K, Kumar R, et al. Comparison of peripherally inserted central venous catheters (PICC) versus subcutaneously implanted port-chamber catheters by complication and cost for patients receiving chemotherapy for non-haematological malignancies. Support Care Cancer. 2014; 22(1): 121–128.
  15. Kąkol M. Wybrane czynniki wpływające na funkcjonowanie portu dożylnego. Rozprawa doktorska. Klinika Chirurgii Onkologicznej. Gdański Uniwersytet Medyczny 2014.
  16. Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2009; 49(1): 1–45.
  17. O'Grady NP, Alexander M, Burns LA, et al. Healthcare Infection Control Practices Advisory Committee (HICPAC) (Appendix 1), Healthcare Infection Control Practices Advisory Committee (HICPAC). Guidelines for the prevention of intravascular catheter-related infections. Clin Infect Dis. 2011; 52(9): e162–e193.
  18. Pronovost P, Needham D, Berenholtz S, et al. An intervention to decrease catheter-related bloodstream infections in the ICU. N Engl J Med. 2006; 355(26): 2725–2732.
  19. Lebeaux D, Fernández-Hidalgo N, Chauhan A, et al. Management of infections related to totally implantable venous-access ports: challenges and perspectives. Lancet Infect Dis. 2014; 14(2): 146–159.
  20. Coady K, Ali M, Sidloff D, et al. A comparison of infections and complications in central venous catheters in adults with solid tumours. J Vasc Access. 2015; 16(1): 38–41.
  21. Justo JA, Bookstaver PB. Antibiotic lock therapy: review of technique and logistical challenges. Infect Drug Resist. 2014; 7: 343–363.
  22. O'Horo JC, Silva GLM, Safdar N. Anti-infective locks for treatment of central line-associated bloodstream infection: a systematic review and meta-analysis. Am J Nephrol. 2011; 34(5): 415–422.
  23. Douard MC, Arlet G, Longuet P, et al. Diagnosis of venous access port-related infections. Clin Infect Dis. 1999; 29(5): 1197–1202.
  24. Debourdeau P, Farge D, Beckers M, et al. International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer. J Thromb Haemost. 2013; 11(1): 71–80.
  25. Akl EA, Kahale L, Neumann I, et al. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev. 2014(6): CD006649.
  26. Calderero AV, de Gregorio AMA. Role of low molecular weight heparins in prophylaxis of thromboembolic events on oncological patients with indwelling central venous catheter. MedClin (Barc). MedClin (Barc). 2009 Sep 19; 133(10): 365–70.
  27. Jan HC, Chou SJ, Chen TH, et al. Management and prevention of complications of subcutaneous intravenous infusion port. Surg Oncol. 2012; 21(1): 7–13.
  28. Nicpoń J, Karczmarek-Borowska B, Pelc M, et al. Żylne cewniki centralne a powikłania. Przegląd Medyczny Uniwersytetu Rzeszowskiego i Narodowego Instytutu Leków w Warszawie. 2014; 1: 97–106.
  29. Pérez Fidalgo JA, García Fabregat L, Cervantes A, et al. ESMO Guidelines Working Group. Management of chemotherapy extravasation: ESMO-EONS Clinical Practice Guidelines. Ann Oncol. 2012; 23 Suppl 7: vii167–vii173.
  30. Girda E, Phaeton R, Goldberg G, et al. Extending the interval for port-a-cath maintenance. Modern Chemotherapy. 2013; 02(02): 15–18.
  31. Ignatov A, Ignatov T, Taran A, et al. Interval between port catheter flushing can be extended to four months. Gynecol Obstet Invest. 2010; 70(2): 91–94.
  32. Dal Molin A, Allara E, Montani D, et al. Flushing the central venous catheter: is heparin necessary? J Vasc Access. 2014; 15(4): 241–248.
  33. Goossens GA, Jérôme M, Janssens C, et al. Comparing normal saline versus diluted heparin to lock non-valved totally implantable venous access devices in cancer patients: a randomised, non-inferiority, open trial. Ann Oncol. 2013; 24(7): 1892–1899.
  34. Donlan RM. Biofilm formation: a clinically relevant microbiological process. J Clin Microbiol. 2001; 32: 2564–2568.
  35. Koldehoff M, Zakrzewski JL. Taurolidine is effective in the treatment of central venous catheter-related bloodstream infections in cancer patients. Int J Antimicrob Agents. 2004; 24(5): 491–495.
  36. Młynarski R, Gawron I, Przesmycki K. Wpływ radioterapii na porty dożylne. Współczesna Onkologia. 2007; 11: 395–398.
  37. Goossens G, Stas M, Moons P. Management of functional complications of totally implantable venous access devices by an advanced practice nursing team: 5 Years of clinical experience. Eur J Oncol Nurs. 2012; 16(5): 465–471.
  38. Hance SN, Glenn LL. Commentary to: Goossens, G.A., Stas, M., Moons, P., 2012. Management of functional complications of totally implantable venous access devices by an advanced practice nursing team: 5 years of clinical experience. Eur J Oncol Nurs. 2012; 16(5): 472.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl